Hassle-free Antibody Discovery

About Us

Experienced. Fast. Affordable.

At Immunovive, we strive to make a difference in the world of immunotherapeutics. Our mission is to accelerate life science research and biologics discovery by providing a high-quality antibody discovery service rapidly and affordably. Our BinderGenᵀᴹ lead discovery platform generates diverse in vivo-derived monoclonal antibody binders in 6 weeks designed to empower downstream drug development applications including target validation, proof-of-concept, lead optimization, and multimodality engineering. The Immunovive team brings decades of expertise, innovation, and leadership that has delivered success to thousands of biotherapeutic investigators worldwide. As a strictly fee-for-service preclinical CRO committed to mobilizing therapeutic ideas to proof-of-concept all rights to the resultant antibodies are 100% retained by the client.

Our Team

Devin E. Turner, Ph.D., Founder and CEO

Devin Turner has over 15 years of successful leadership in antibody discovery companies. Most recently, Devin was the Head of Antibody Discovery Services at Alloy Therapeutics where he led a world-class multidisciplinary team delivering fully human antibody-based therapeutic leads from Alloy’s state-of-the-art suite of humanized mice. Prior to Alloy Devin founded Abveris, a biotech company based on a unique technology Devin had created to address unmet needs in biotherapeutics research. In six years, Devin led Abveris through substantial growth, technological creation, and a successful exit while delivering scores of IND-enabling therapeutic lead molecules to a broad range of human diseases. Devin continues his passion for immunotherapeutics through his latest company, Immunovive, which accelerates biologics discovery and research by providing access to a robust in vivo-based hit generation platform free of IP encumbrances. Devin earned his B.S. in Molecular, Cellular, and Developmental Biology from UCLA and his Ph.D. in Immunology from Harvard Medical School.

Rashed Abdullah, Ph.D., PMP, Associate Director of Operations and Business Development

Dr. Rashed Abdullah is a seasoned scientist with over two decades of experience in therapeutic antibody discovery, oncology, vaccine development, and neurodegenerative disease research. A certified Project Management Professional (PMP), he has led R&D programs and cross-functional teams across biotech and CRO environments. His expertise spans monoclonal and polyclonal antibody development, AOC/ADC platforms, assay design, and preclinical strategy. Dr. Abdullah has held leadership roles at Gennao Bio, Abveris (now Twist Bio), and Immunovive LLC, where he currently serves as Associate Director of Operations and Business Development. He holds a Ph.D. in Biology from St. John's University and has contributed to numerous peer-reviewed publications in the field of therapeutic discovery.

Tom Daly, Jr., M.Sc., Scientist

Tom has over 17 years combined experience in drug discovery, particularly using in vivo models in disease areas of cancer and autoimmune diseases. Throughout his career he has dedicated his efforts to discover and develop drug therapies such as Necuparanib, which reached Phase II; CTX-471, currently in Phase I clinical trials; and others that are still in preclinical stage development. He was also on the initial development team for Nipoclamib, an anti-FcRn approved by the FDA in April 2025. Tom has developed tumor, platelet depletion, and rescue in vivo models, as well as other pharmacokinetic models. Most recently at Alloy Therapeutics and now here at Immunovive, he has specialized in the generation of monoclonal hybridoma colonies from mouse B cells that generate target specific antibodies for customer projects and is dedicated to the delivery of a potential drug target for clients. He earned his Masters Degree in Biotechnology from Worcester State University.